Since Humira has about 25% of the RA/autoimmune market, a $250M hit to Humira in 2015 from PFE’s JAK3 inhibitor is consistent with 2015 sales of about $1B for PFE’s drug. I don’t consider such a forecast out of line.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”